Biotech and Pharma

Novo Nordisk has agreed to sell its weight-loss injectables and its Wegovy pill on Hims’ platform.

Marvell shares jump after the chip maker beats analysts’ fourth-quarter earnings estimates and issues solid guidance.

Servier agrees to buy Day One Biopharmaceuticals in an all-cash deal for $21.50 a share.

Shares in Broadcom rise after the chip maker beats Wall Street’s earnings targets for its fiscal first quarter.

Software stocks have taken a beating lately, but Veeva looks well-placed to weather the market’s artificial intelligence fears.

The company settles to resolve patent litigation related to its Covid-19 vaccine, removing an overhang for shares.

The U.S. Food and Drug Administration rejects the biotech company’s AMT-130 gene therapy.

The diagnostics company’s stock climbed fivefold last year, but it dropped in half Friday.

Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.

Advanced Micro Devices rallies after the chip maker unveils a multiyear deal to supply computing power to Meta Platforms.

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

Hims & Hers, the telehealth provider best known for its compounded weight-loss drugs, issues a weak outlook.

The Danish drugmaker released a promising update about a trial in China, but that didn’t end a rough run for shares.

Waller calls March rate decision a coin flip, a viral online post slams stocks, tariff refunds are in play, and more news to start your day.

Novo Nordisk stock sinks after new trial data show weight-loss drug candidate CagriSema is less effective than a rival treatment from Eli Lilly.

Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.

Novo shares slump after the Danish drugmaker’s experimental obesity drug fails to beat Lilly’s treatment in an 84-week trial.

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in stage 3 and 4 cancer in a U.K. trial.

Nvidia sold its entire stake in a drug-discovery company at the end of last year. ARK Invest is buying the stock.

Hims & Hers Health will buy Eucalyptus, an Australian digital health company, in a deal valued at $1.15 billion.

Fed meeting minutes put rate hikes back on the table, New York Fed’s tariff research draws administration’s ire, Carvana’s murky outlook disappoints, and more news to start your day.

Nvidia shares rise after Meta Platforms expands an existing partnership with the AI chip designer.

The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.

Paramount Skydance stock rises after Warner Bros. Discovery says it will restart deal talks with the company.